HC Wainwright Has Positive View of OTCMKTS:MDNAF Q1 Earnings

Medicenna Therapeutics Corp. (OTCMKTS:MDNAF) – Equities research analysts at HC Wainwright upped their Q1 2027 earnings per share (EPS) estimates for Medicenna Therapeutics in a report released on Thursday, July 2nd. HC Wainwright analyst S. Ramakanth now forecasts that the company will post earnings of ($0.04) per share for the quarter, up from their prior forecast of ($0.05). The consensus estimate for Medicenna Therapeutics’ current full-year earnings is ($0.20) per share. HC Wainwright also issued estimates for Medicenna Therapeutics’ Q2 2027 earnings at ($0.04) EPS, Q3 2027 earnings at ($0.04) EPS, Q4 2027 earnings at ($0.04) EPS, FY2027 earnings at ($0.17) EPS and FY2028 earnings at ($0.07) EPS.

Medicenna Therapeutics (OTCMKTS:MDNAF) last released its quarterly earnings data on Thursday, June 25th. The company reported ($0.05) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.05).

Medicenna Therapeutics Price Performance

MDNAF stock opened at $0.26 on Tuesday. Medicenna Therapeutics has a 1-year low of $0.25 and a 1-year high of $1.43. The business’s 50 day simple moving average is $0.35. The firm has a market cap of $24.24 million, a price-to-earnings ratio of -1.64 and a beta of 1.75.

About Medicenna Therapeutics

Medicenna Therapeutics Corp. is a clinical-stage biopharmaceutical company focused on developing next-generation cytokine-based immunotherapies for cancer and central nervous system disorders. The company applies protein-engineering approaches to create engineered cytokine therapeutics designed to enhance anti-tumor activity while reducing systemic toxicity, aiming to broaden the therapeutic window for immunomodulatory agents.

Medicenna’s pipeline includes proprietary candidates such as MDNA55, an engineered interleukin-4 (IL-4) receptor-targeted fusion protein developed for intratumoral treatment of recurrent glioblastoma and other brain tumors, and MDNA11, a long-acting engineered interleukin-2 (IL-2) “superkine” intended to stimulate anti-tumor immune responses in solid tumors with an improved safety profile.